Revenue Breakdown
Composition ()
No data
Revenue Streams
Danaher Corp (DHR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Diagnostics, accounting for 40.7% of total sales, equivalent to $2.46B. Other significant revenue streams include Biotechnology and Life Sciences. Understanding this composition is critical for investors evaluating how DHR navigates market cycles within the Advanced Medical Equipment & Technology industry.
Profitability & Margins
Evaluating the bottom line, Danaher Corp maintains a gross margin of 58.20%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 22.17%, while the net margin is 17.30%. These profitability ratios, combined with a Return on Equity (ROE) of 7.05%, provide a clear picture of how effectively DHR converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, DHR competes directly with industry leaders such as SYK and MDT. With a market capitalization of $145.67B, it holds a significant position in the sector. When comparing efficiency, DHR's gross margin of 58.20% stands against SYK's 62.61% and MDT's 59.93%. Such benchmarking helps identify whether Danaher Corp is trading at a premium or discount relative to its financial performance.
